Replies to post #212111 on Amarin Corp Plc (AMRN)

[couldbebetter]

Pharmacydude, All very good questions. Even if AMRN loses to generics
in the US, my understanding is that Europe would be good for 10 or 11
years which is a market as valuable as would be the US...so that would
be a reason for AMRN to still be acquired. Given the strong cash position
of AMRN I wonder if that could be used in a way that could bolster the
legal fight to give AMRN an edge. Hopefully, AMRN would have a number of
strategies to keep generics off the market. Does anyone know what other
strategies AMRN might employ?

[ziploc_1]

P...In retrospect, settling with Teva was a mistake...even though it cost Amarin only $2 million.

Amarin has a multitude of strong patents...many small and large pharmas will inevitably be tempted to pile on, hoping for a cash settlement...

Amarin spent hundreds of millions of dollars pursuing R-IT...in order to prove to the FDA that Vascepa was safe and effective...they should earmark more hundreds of millions for proving in court that their patents are strong...and they should refuse to be be ripped off by infringers and free loaders, who spent nothing on the science and are hoping to profit on the back of Amarin.